Ubs Group Ag Mainz Biomed N.V. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.88 - $1.2 $2,822 - $3,848	3,207 New	3,207 $3,000
Q3 2023 Nov 09, 2023	SELL	$2.89 - $4.9 $2,407 - $4,081	-833 Reduced 89.47%	98 $0
Q2 2023 Aug 11, 2023	SELL	$3.42 - $6.49 $4,353 - $8,261	-1,273 Reduced 57.76%	931 $4,000
Q1 2023 May 12, 2023	SELL	$6.08 - $7.22 $97 - $115	-16 Reduced 0.72%	2,204 $13,000
Q4 2022 Feb 08, 2023	BUY	$6.31 - $9.38 $14,008 - $20,823	2,220 New	2,220 $15,000
Q2 2022 Aug 10, 2022	SELL	$8.91 - $15.5 $721 - $1,255	-81 Reduced 5.61%	1,364 $13,000
Q1 2022 May 16, 2022	SELL	$10.39 - $27.76 $75,483 - $201,676	-7,265 Reduced 83.41%	1,445 $21,000
Q4 2021 Feb 14, 2022	BUY	$8.05 - $26.46 $70,115 - $230,466	8,710 New	8,710 $90,000

103K

Ticker MYNZ
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 14,483,000
Market Cap $3.04M
Description
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.